Compare NetEase Inc (NTES) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Organon & Co. Common Stock — how do they compare? NetEase Inc trades at $125.02 (market cap $79.76B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: NetEase Inc is far larger — about 22× Organon & Co. Common Stock's market cap, and NetEase Inc pays the higher dividend (2.35%). Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Organon & Co. Common Stock for 0 Days on average.
| NTES | OGN | |
|---|---|---|
Market Cap | $79.76B | $3.62B |
Volume | 503,697 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $152.85 | $13.81 |
52-Week Low | $109.26 | $5.70 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $55.44B | $11.04B |
Dividend Yield | 2.35% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $123.73, down 1.34% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $4.4 billion, an 8% year-over-year increase, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights global expansion and AI investments as key growth drivers.
The outlook remains positive with an 81.82% analyst buy rating and a consensus price target of $168.00, implying significant upside. Key risks include earnings volatility, competitive pressures in gaming, and macroeconomic sensitivity. The stock's current valuation at a P/E of 16.58 offers a reasonable entry point for long-term growth investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
